Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sino BiopharmaceuticalSBMFF +6.70%61 EV-to-EBITDA is 12.02 as of Aug. 17, 2026, which is 9% above its 10-year median of 11.07. GuruFocus rates SBMFF with a GF Score™ of 61/100 and a GF Value™ of $0.69 (Fairly Valued). The stock has 4 warning signs investors should review. Among 401 Biotechnology companies, Sino Biopharmaceutical ranks better than 54.86% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Sino Biopharmaceutical's enterprise value is $12,126 Mil.
Sino Biopharmaceutical's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $1,009 Mil. Therefore, Sino Biopharmaceutical's EV-to-EBITDA for today is 12.02.
The historical rank and industry rank for Sino Biopharmaceutical's EV-to-EBITDA or its related term are showing as below:
SBMFF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 3.11 Med: 11.07 Max: 25.59
Current: 12.02
During the past 13 years, the highest EV-to-EBITDA of Sino Biopharmaceutical was 25.59. The lowest was 3.11. And the median was 11.07.
SBMFF's EV-to-EBITDA is ranked better than 54.86% of 401
companies
in the Biotechnology industry
Industry Median: 13.8
vs SBMFF: 12.02
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Sino Biopharmaceutical (OTCPK:SBMFF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sino Biopharmaceutical's PE Ratio (TTM) for today is calculated as:
Sino Biopharmaceutical's share price for today is $0.6509.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sino Biopharmaceutical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.018.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SBMFF vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Sino Biopharmaceutical's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sino Biopharmaceutical EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sino Biopharmaceutical's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Sino Biopharmaceutical's EV-to-EBITDA falls into.
Sino Biopharmaceutical's current Enterprise Value is $12,126 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sino Biopharmaceutical's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $1,009 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sino Biopharmaceutical (SBMFF) has a EV-to-EBITDA of 12.02 as of Aug. 17, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Sino Biopharmaceutical. This is near median its historical median of 11.07. Over the past decade, Sino Biopharmaceutical's EV-to-EBITDA has ranged from 3.11 to 25.59. According to the industry distribution chart, Sino Biopharmaceutical ranks #181 out of 401 companies in the Biotechnology industry, placing it in the top 45.1%.
Is Sino Biopharmaceutical's EV-to-EBITDA too high?
Sino Biopharmaceutical's current EV-to-EBITDA of 12.02 is near median its 10-year median of 11.07. Over the past 10 years, this metric has ranged from a low of 3.11 to a high of 25.59. The Biotechnology industry median EV-to-EBITDA is 13.80. Sino Biopharmaceutical's value of 12.02 is 12.9% below this industry median. Based on the distribution chart, Sino Biopharmaceutical ranks #181 out of 401 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Sino Biopharmaceutical has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sino Biopharmaceutical's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sino Biopharmaceutical ranks #181 out of 401 companies for EV-to-EBITDA. This puts Sino Biopharmaceutical in the upper half of its industry. The industry median EV-to-EBITDA is 13.80. Sino Biopharmaceutical's value of 12.02 is 12.9% below this benchmark. Historically, Sino Biopharmaceutical's own EV-to-EBITDA has ranged from 3.11 to 25.59 over the past decade. While the company's 10-year median is 11.07 vs. the industry median of 13.80, Sino Biopharmaceutical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.80, based on 401 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sino Biopharmaceutical's current EV-to-EBITDA of 12.02 is 12.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Sino Biopharmaceutical. For the Biotechnology industry, the median EV-to-EBITDA is 13.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sino Biopharmaceutical's current EV-to-EBITDA is 12.02, which is near median its own 10-year median of 11.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sino Biopharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Sino Biopharmaceutical (SBMFF) is currently considered Fairly Valued. The stock's GF Value™ is $0.69, compared to a current price of $0.65 — trading 5.7% below its estimated fair value. The current EV-to-EBITDA is 12.02, which is near median its 10-year median of 11.07 and 12.9% below the Biotechnology industry median of 13.80. Sino Biopharmaceutical's overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Sino Biopharmaceutical (SBMFF), the current EV-to-EBITDA is 12.02 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sino Biopharmaceutical (SBMFF) Overvalued in 2026?
Based on GuruFocus' analysis, Sino Biopharmaceutical stock appears to be undervalued.
The current stock price of $0.65 is trading 5.7% below its estimated GF Value™ of $0.69.
GuruFocus considers Sino Biopharmaceutical to be Fairly Valued.
Key valuation signals for SBMFF:
EV-to-EBITDA: 12.02 (near median its 10-year median of 11.07)
GF Value™: $0.69 vs. price of $0.65 (5.7% below fair value)
Industry Position: 12.9% below the Biotechnology median (#181 of 401)
No single metric tells the full story. See the SBMFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sino Biopharmaceutical Ltd is an investment holding company. The company and its subsidiaries are principally engaged in the research and development, production and sale of a series of pharmaceutical products. Its business covering the entire industrial chain of R&D, production and commercialization of drugs, biological products and high-end generic drugs. The company's therapeutic areas include: oncology, liver disease, respiratory, and surgery/pain relief. The company's revenue was generated from the sale of pharmaceutical products in the Chinese mainland.
61GF Score
Get the complete analysis for SBMFF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SBMFF has been successfully added to your 
